- AUY922 (NVP-AUY922)
- PF-04929113 (SNX-5422)
- IPI-504 (Retaspimycin hydrochloride)
- XL-888
- MPC-3100
- AT13387
| BIIB021Hsp90 inhibitor,selective and competitive |
Sample solution is provided at 25 µL, 10mM.
Nature.2017 Jan 19;541(7637):417-420.
Nature.2018 Nov;563(7731):407-411.Nature.2018 Jun 13.Nature.2018 Jun 27.Nature.2018 Mar 29;555(7698):673-677.Nature.2017 Sep 7;549(7670):96-100.Nature.2016 Apr 21;532(7599):398-401.
Science.2016 Aug 5;353(6299)594-8Nat Nanotechnol.2017 Dec;12(12):1190-1198.Nature Biotechnology.2017 Jun;35(6):569-576Nat Med.2018 Sep 17.Cell.2018 Dec 21. pii: S0092-8674(18)31561-7.Cell.Available online 25 October 2018.Cell.2018 Sep 27. pii: S0092-8674(18)31183-8.Cell.2018 Jun 28;174(1):172-186.e21.Cell.2018 Feb 22;172(5):1007-1021.e17.Cell.2017 Nov 30;171(6):1284-1300.e21.Cell.2017 Aug 17. pii: S0092-8674(17)30869-3.Cell.2017 Jul 13;170(2):312-323Nat Med.2018 Jan 29.Nat Med.2017 Nov;23(11):1342-1351.Cell.2017 Apr 6;169(2):286-300.Cell.2015 Aug 27;162(5):987-1002.Cell.2015 Feb 12;160(4):729-44.Nature Medicine.2017 Apr;23(4):493-500.Cancer Cell.2018 May 14;33(5):905-921.e5.Cancer Cell.2018 Apr 9;33(4):752-769.e8.Cancer Cell.2018 Mar 12;33(3):401-416.e8.Cancer Cell.2017 Aug 14;32(2):253-267.e5.Nat Methods.2018 Jul;15(7):523-526.Cell Stem Cell.2018 May 3;22(5):769-778.e4.Cell Stem Cell.2017 Nov 20. pii: S1934-5909(17)30375-2.Quality Control & MSDS
- View current batch:
- Purity = 99.51%
- COA (Certificate Of Analysis)
- HPLC (Retest)
- NMR (Nuclear Magnetic Resonance)
- MSDS (Material Safety Data Sheet)
- Datasheet
Chemical structure
| Description | BIIB021 is a selective and competitive inhibitor of Hsp90 with Ki value of 1.7 nM. | |||||
| Targets | Hsp90 | |||||
| IC50 | 1.7 nM (Ki) | |||||
BIIB021 Dilution Calculator
calculate
BIIB021 Molarity Calculator
calculate
| Cas No. | 848695-25-0 | SDF | Download SDF |
| Synonyms | N/A | ||
| Chemical Name | 6-chloro-9-[(4-methoxy-3,5-dimethylpyridin-2-yl)methyl]purin-2-amine | ||
| Canonical SMILES | CC1=CN=C(C(=C1OC)C)CN2C=NC3=C2N=C(N=C3Cl)N | ||
| Formula | C14H15ClN6O | M.Wt | 318.8 |
| Solubility | ≥14.95 mg/mL in DMSO, <2.44 mg/ml="" in="" etoh,=""><2.52 mg/ml="" in="" h2o=""> | Storage | Store at -20°C |
| Physical Appearance | A solid | Shipping Condition | Evaluation sample solution : ship with blue ice.All other available size:ship with RT , or blue ice upon request |
| General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. | ||
BIIB021 is a selective inhibitor of Hsp90 with Ki and EC50 values of 1.7 nM and 38 nM, respectively.[1] HSP90 (heat shock protein 90) is widely expressed as a molecular chaperone. It plays a major role in the folding and stabilization of cellular proteins. HSP90 protects client proteins from degradation and maintains them in an active conformation. Many clients of HSP90 are transcription factors or protein kinases such as: Bcr-Abl, tyrosine kinases, EGFR family members, IGF1-R, c-Met, steroid hormone receptors, p53, Mdm2 and telomerase. In a variety of cancers, overexpressed hsp90 has been found. Hsp90 also play an important role in maintaining the transformed phenotype of cancer cells so. Hsp 90 is one attractive target for cancer therapy.[2]BIIB021 competitive binds in the ATP-binding pocket and inhibits Hsp90 chaperone function, and lead to client protein degradation, cell death and tumor growth inhibition. BIIB021 leads to degradation of HER-2 which is an Hsp90 client protein. BIIB021 can also the growth of a variety of cancer cell lines in cell proliferation assays. In MCF-7 cells, BIIB021 leaded to HER-2 degradation with the EC50 value of was38 ± 10 nmol/L. BIIB021 inhibit the cell proliferation with IC50 values of 0.06 μ mol/L in N87 cells, 0.31μ mol/L in MCF-7 cells and 0.14 μ mol/L in BT474 cells. In MCF-7 cells, BIIB021 significantly reduced the phosphorylation levels of HER-2 at a concentration of 50 nM.[1] BIIB021 selectively inhibited Hodgkin"s lymphoma cell viability at nanomolar concentrations but not in lymphocytes from healthy individuals. BIIB021 can increase the susceptibility to NK cell mediated killing by inducing the expression of ligands for the activating NK cell receptor NKG2D on Hodgkin"s lymphoma cells.[3] BIIB021 reduced the expression of key radioresponsive proteins, then enhanced the radiosensitivity of HNSCCA cell lines in vitro, increased apoptosis cells and induced G2 arrest.[2]BIIB021 showed significant activity at doses of 31,62.5, and 125 mg/kg in human in nude mice bearing N87 stomach carcinoma tumors.[1] HSP90 significantly inhibited tumor growth in a xenograft model of Hodgkin"s lymphoma.[1]References: 1.Lundgren K, Zhang H, Brekken J, Huser N, Powell RE, Timple N, Busch DJ, Neely L, Sensintaffar JL, Yang YC et al: BIIB021, an orally available, fully synthetic small-molecule inhibitor of the heat shock protein Hsp90. Mol Cancer Ther 2009, 8(4):921-929.2.Yin X, Zhang H, Lundgren K, Wilson L, Burrows F, Shores CG: BIIB021, a novel Hsp90 inhibitor, sensitizes head and neck squamous cell carcinoma to radiotherapy. Int J Cancer 2010, 126(5):1216-1225.3.Boll B, Eltaib F, Reiners KS, von Tresckow B, Tawadros S, Simhadri VR, Burrows FJ, Lundgren K, Hansen HP, Engert A et al: Heat shock protein 90 inhibitor BIIB021 (CNF2024) depletes NF-kappaB and sensitizes Hodgkin"s lymphoma cells for natural killer cell-mediated cytotoxicity. Clin Cancer Res 2009, 15(16):5108-5116.
ebiomall.com
>
>
>
>
>
>
>
>
>
>
>
>
蛋白的类型为PDGF。其有一种二聚体为PDGF-BB。
请教第一点：我看了Elisa的说明书，现在检测PDGF有两种试剂盒，一种是检测PDGF的，要求的试剂样本为组织匀浆；一种是检测PDGF-BB的，要求的待测样本为血液或血浆。
我现在的实验目的是想更精确，检验组织中的PDGF-BB，但是手中的是人体韧带组织样本，非PDGF-BB试剂盒所要求的组织样本为血浆或血清，我不知道是否可以用PDGF-BB的ELISA试剂盒的来做，所以特地请教：）
请教第二点：市面上有RB公司的96T，2500元；另外有Uscnlife的Elisa试剂盒，96T的3680元，都说是原装进口的，我该如何选择呢？为何差价这么多？谢谢指点！
一、免疫组化试剂盒一般包括：
1、特异性的一抗
2、免疫组化检测系统。
3、有的同时还具备显色系统。
二、不同的公司内容有差别，所以购买时一定了解清楚：
1、一抗是做人的还是兔、鼠的组织；
2、检测系统是ABC/SP/非生物素/其他；
3、试剂盒的内容都有什么？有没有显色系统？
4、如果没有，自己根据前面的检测系统需配哪个显色系统。（其他的辅助试剂如PBS缓冲液、抗原修复液等一般另卖或自配）
三、免疫组化抗体即指特异性一抗，是用来标记的指标，免疫组化过程的其他试剂一律另外配备。
另外：做实验时，如遇出结果困难，记得做阳性片对照，敢于怀疑检测系统或显色系统的问题。
